Annual report pursuant to Section 13 and 15(d)

Segment reporting (Tables)

v3.19.3
Segment reporting (Tables)
 12 Months Ended
Jul. 31, 2019
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment [Table Text Block] The following financial information represents the operating results of the reportable segments of the Company:

Year ended July 31, 2019   Clinical
Laboratory
Services		     Life
Sciences
Products		     Therapeutics     Other     Consolidated  
Revenues   $ 51,115     $ 30,055     $ —     $ —     $ 81,170  
                                         
Operating costs, expenses and legal settlements, net:                                        
Cost of revenues     44,226       13,696       —       —       57,922  
Research and development     31       2,257       887       —       3,175  
Selling, general and administrative     24,230       11,860       —       8,175       44,265  
Legal fee expense     159       27       —       2,814       3,000  
Legal settlements, net     —       (28,925 )     —       —       (28,925 )
Total operating costs, expenses and legal settlements, net     68,646       (1,085 )     887       10,989       79,437  
                                         
Operating income (loss)     (17,531 )     31,140       (887 )     (10,989 )     1,733  
                                         
Other income (expense) Interest     (64 )     67       —       1,053       1,056  
Other     16       2       —       364       382  
Foreign exchange loss     —       (682 )     —       —       (682 )
Income (loss) before taxes   $ (17,579 )   $ 30,527     $ (887 )   $ (9,572 )   $ 2,489  
                                         
Depreciation and amortization included above   $ 1,625     $ 1,221     $ —     $ 190     $ 3,036  
                                         
Share-based compensation included above:                                        
                                         
Selling, general and administrative     147       95       —     $ 697       939  
Total   $ 147     $ 95     $ —     $ 697     $ 939  
                                         
Capital expenditures   $ 1,374     $ 605     $ —     $ 6,147     $ 8,126  
Year ended July 31, 2018   Clinical
Laboratory
Services		     Life
Sciences
Products		     Therapeutics     Other     Consolidated  
Revenues   $ 71,077     $ 29,936     $ —     $ —     $ 101,013  
                                         
Operating costs, expenses and legal settlements, net:                                        
Cost of revenues     46,008       14,377       —       —       60,385  
Research and development     —       2,305       905       —       3,210  
Selling, general and administrative     24,656       11,617       —       8,182       44,455  
Legal fee expense     67       58       —       5,002       5,127  
Total operating costs, expenses and legal settlements, net     70,731       28,357       905       13,184       113,177  
                                         
Operating income (loss)     346       1,579       (905 )     (13,184 )     (12,164 )
                                         
Other income (expense) Interest     (91 )     50       —       894       853  
Other     29       11       —       128       168  
Foreign exchange loss     —       (275 )     —       —       (275 )
Income (loss) before taxes   $ 284     $ 1,365     $ (905 )   $ (12,162 )   $ (11,418 )
                                         
Depreciation and amortization included above   $ 1,667     $ 1,387     $ —     $ 76     $ 3,130  
                                         
Share-based compensation included in above:                                        
Selling, general and administrative     125       79       —     $ 609       813  
Total   $ 125     $ 79     $ —     $ 609     $ 813  
                                         
Capital expenditures   $ 1,685     $ 203     $ —     $ —     $ 1,888  
Year ended July 31, 2017   Clinical
Laboratory
Services		     Life
Sciences
Products		     Therapeutics     Other     Consolidated  
Total revenues   $ 74,689     $ 30,397     $ —     $ —     $ 105,086  
                                         
Operating costs, expenses and legal settlements, net:                                        
Cost of product revenues     45,400       14,078       —       —       59,478  
Research and development     —       2,311       617       —       2,928  
Selling, general and administrative     24,465       11,289       —       8,395       44,149  
Legal fee expense     146       79       —       1,454       1,679  
Total operating costs, expenses and legal settlements, net     70,011       27,757       617       9,849       108,234  
                                         
Operating income (loss)     4,678       2,640       (617 )     (9,849 )     (3,148 )
                                         
Other income (expense)                                        
Interest     (112 )     46       —       450       384  
                                         
Other     137       (60 )     —       48       125  
Foreign exchange gain     —       135       —       —       135  
Income (loss) before taxes   $ 4,703     $ 2,761     $ (617 )   $ (9,351 )   $ (2,504 )
                                         
Depreciation and amortization included above   $ 1,586     $ 1,913     $ —     $ 99     $ 3,598  
                                         
Share-based compensation included above:                                        
Cost of clinical laboratory services   $ 6     $ —     $ —     $ —     $ 6  
Selling, general and administrative     111       74       —     $ 640       825  
Total   $ 117     $ 74     $ —     $ 640     $ 831  
                                         
Capital expenditures   $ 1,363     $ 390     $ —     $ —     $ 1,753  
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Geographic financial information is as follows:

Net sales to unaffiliated customers:   2019     2018     2017  
United States   $ 72,387     $ 91,688     $ 96,751  
Switzerland     2,611       2,584       2,371  
United Kingdom     1,611       1,851       1,673  
Other international countries     4,561       4,890       4,291  
Total   $ 81,170     $ 101,013     $ 105,086  
                         
Long-lived assets at July 31,   2019     2018          
United States   $ 22,057     $ 16,210          
Switzerland     376       502          
United Kingdom     64       127          
Other international countries     96       135          
Total   $ 22,593     $ 16,974          
Schedule of Segment Revenue By Geographical [Table Text Block] The following is a summary of the Life Sciences Products segment revenues attributable to customers located in the United States and foreign countries:

    2019     2018     2017  
United States   $ 21,272     $ 20,610     $ 22,062  
Foreign countries     8,783       9,326       8,335  
    $ 30,055     $ 29,936     $ 30,397